Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Creaven

Showing results (11-20 of 130) with videos related to

Pageof 13
Sort By:
European Journal of Cancer|October 1, 1975
Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivativesL M Allen, P J Creaven
Cancer Chemotherapy Reports|April 1, 1973
Renal clearance of camptothecin (NSC-100880): effect of urine volumeP J Creaven, L M Allen
Cancer Chemotherapy Reports|July 1, 1975
Human pharmacokinetic model for isophosphamide (NSC-1097241)L M Allen, P J Creaven
Journal of Pharmaceutical Sciences|December 1, 1972
Effect of microsomal activation on interaction between isophosphamide and DNAL M Allen, P J Creaven
Cancer Research|December 1, 1973
Inhibition of macromolecular biosynthesis in cultured L1210 mouse leukemia cells by thalicarpine (NSC 68075)L M Allen, P J Creaven
Cancer Chemotherapy Reports|October 1, 1972
In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomesL M Allen, P J Creaven
International Endodontic Journal|November 1, 1993
Antibacterial properties of eight dental cementsM M Coogan, P J Creaven
Journal of the National Cancer Institute|December 7, 1988
Symposium on the expanding role of folates and fluoropyrimidines in cancer chemotherapyY M Rustum, P J Creaven
Clinical Pharmacology and Therapeutics|August 1, 1975
EPEG, a new antineoplastic epipodophyllotoxinP J Creaven, L M Allen
Clinical Pharmacology and Therapeutics|April 1, 1975
Pharmacokinetics of ifosfamideL M Allen, P J Creaven
Pageof 13

Showing results (11-20 of 130) with videos related to

Sort By:
Pageof 13
European Journal of Cancer|October 1, 1975
Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivativesL M Allen, P J Creaven
Cancer Chemotherapy Reports|April 1, 1973
Renal clearance of camptothecin (NSC-100880): effect of urine volumeP J Creaven, L M Allen
Cancer Chemotherapy Reports|July 1, 1975
Human pharmacokinetic model for isophosphamide (NSC-1097241)L M Allen, P J Creaven
Journal of Pharmaceutical Sciences|December 1, 1972
Effect of microsomal activation on interaction between isophosphamide and DNAL M Allen, P J Creaven
Cancer Research|December 1, 1973
Inhibition of macromolecular biosynthesis in cultured L1210 mouse leukemia cells by thalicarpine (NSC 68075)L M Allen, P J Creaven
Cancer Chemotherapy Reports|October 1, 1972
In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomesL M Allen, P J Creaven
International Endodontic Journal|November 1, 1993
Antibacterial properties of eight dental cementsM M Coogan, P J Creaven
Journal of the National Cancer Institute|December 7, 1988
Symposium on the expanding role of folates and fluoropyrimidines in cancer chemotherapyY M Rustum, P J Creaven
Clinical Pharmacology and Therapeutics|August 1, 1975
EPEG, a new antineoplastic epipodophyllotoxinP J Creaven, L M Allen
Clinical Pharmacology and Therapeutics|April 1, 1975
Pharmacokinetics of ifosfamideL M Allen, P J Creaven
Pageof 13